MAREZINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAREZINE is an injectable small-molecule product approved by GSK in 1954 for the treatment of motion sickness and nausea. The specific mechanism of action is not documented in available data, but the product has remained in clinical use for over 70 years. This legacy therapeutic is now approaching loss of exclusivity.
LOE Approaching
With LOE approaching and moderate competitive pressure (30%), the brand team is likely focused on retention and cost-management strategies rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on MAREZINE offers limited career growth potential given its late-lifecycle stage and minimal linked job openings. Roles available are primarily focused on portfolio maintenance, compliance, and managing competitive erosion rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on MAREZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.